Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 13/20 | 0.58 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.58 |
| ▸ | CDK1 | P06493 | 1/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.58 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.58 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27652251 | 0.78 | RIPK1 (0.50) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| Hydrochloric Acid SCHEMBL27719521 | 0.77 | RIPK1 (0.49) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL15566492 | 0.76 | DAO (0.51) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL29588694 | 0.76 | ALDH1A1 (0.55) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL12333 | 0.75 | DAO (0.53) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL575029 | 0.75 | DAO (0.53) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1778522 | 0.74 | RIPK1 (1.00) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31064954 | 0.74 | RIPK1 (1.00) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31710670 | 0.74 | RIPK1 (0.61) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL27889519 | 0.73 | CCNB2 (0.68) | RIPK1CCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | RAPPORT THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| CN-111065393-A | Pyrrolopyridine-anilines for the treatment of skin diseases | 恩福莱克逊治疗有限公司 | 2020-04-24 | — | — | CN | disclosed |
| US-9593108-B2 | Compounds and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| EP-1885723-A2 | PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2007013896-A2 | PYRROL (2,3-B) PYRIDINE DERIVATIVES PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140205537-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, MAP2 | RIPK1 144/4885CCNB2 3230/4885CDK1 619/4885 |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | RIPK1 2340/4885CCNB2 2360/4885CDK1 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.